Clinical trials: Cancer, Advanced
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
This phase II/III Lung-MAP trial studies how well immunotherapy treatment with N-803 (ALT-803) and pembrolizumab working in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced).
- Conditions
- Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT05096663
- Testing
- Cobalamin, Dexamethasone, Docetaxel
- Where
- 350 sites in United States
- Volunteers
- 82 people
- Sponsor
- SWOG Cancer Research Network
Mesenchymal Chondrosarcoma
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
- Trial name
- ISG-MCS (NCT04305548)
- Testing
- Trabectedin
- Where
- 7 sites in Italy
- Volunteers
- 16 people
- Sponsor
- Italian Sarcoma Group
Prostate Cancer
Investigation of Tumor Microenvironment After CRPC Along With Before and After Neoadjuvant Therapy for Prostate Cancer
In recent years, the clinical research of immunotherapy including PD-1 antibody and CD3 bispecific antibody in prostate cancer has been increasing day by day.
- Trial name
- NCT05522907
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Sarcoma
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
What is this study about? This is a medical research study testing a new drug combination ("Paclitaxel Polymer Micelles" + "Gemcitabine" + "Targeted Therapy") for patients with locally advanced unresectable or metastatic bone and…
- Trial name
- MAGNATE-S (NCT07359053)
- Testing
- Paclitaxel Polymer Micelles + Gemcitabine + Lenvatinib, Paclitaxel Polymer Micelles + Gemcitabine + Anlotinib
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Shanghai 6th People's Hospital
Hodgkin Lymphoma
Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window Study
This is a phase II, non-randomised, multicentre study to assess the safety and efficacy of the PD-L1 inhibitor, avelumab, in a previously untreated fit population of high risk stage II, stage III and stage IV classical Hodgkin…
- Trial name
- AVENuE (NCT03617666)
- Testing
- Avelumab
- Where
- 11 sites in Australia, United Kingdom
- Volunteers
- 49 people
- Sponsor
- University College, London
Hepatocellular Carcinoma, Laser Ablation
Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Hepatocellular carcinoma (HCC) is the fifth most-common cancer worldwide and the second most-common cause of cancer mortality. Liver resection is the first-line curative treatment for huge HCC.
- Conditions
- Hepatocellular Carcinoma, Laser Ablation, Portal Vein Tumor Thrombus
- Trial name
- NCT02724475
- Testing
- LA, 3D-CRT
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Cancer Metastatic
Improving Public Cancer Care by Implementing Precision Medicine in Norway
IMPRESS-Norway is a prospective, non-randomized clinical trial evaluating efficacy of commercially available, anti-cancer drugs prescribed for patients with advanced cancer diagnosed with potentially actionable alterations as…
- Trial name
- IMPRESS-N (NCT04817956)
- Testing
- Atezolizumab
- Where
- 17 sites in Norway
- Volunteers
- 3,000 people
- Sponsor
- Oslo University Hospital
Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients Receiving Neoadjuvant/Preoperative Chemotherapy
The goal of this clinical trial is to learn if olanzapine works to prevent and treat anorexia-cachexia syndrome and appetite loss in cancer patients.
- Conditions
- Oncology Patients Receiving Chemotherapy, Cachexia-Anorexia Syndrome, Oncology
- Trial name
- NCT07633236
- Testing
- OLANZapine 2.5 MG
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Neoplasms, Solid Tumors
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
This is a Phase 1/1B, non-randomized, open-label, dose-escalation study of robatumumab (SCH 717454, MK-7454) administered in combination with chemotherapy in pediatric participants with solid tumors, to be conducted in…
- Conditions
- Neoplasms, Solid Tumors, Bone Cancer, Kidney Tumor
- Trial name
- NCT00960063
- Testing
- Temozolomide, Vincristine, Ifosfamide
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Sarcoma
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft tissue sarcoma previously treated with anthracycline and/or ifosfamide 1. Primary endpoint: response rate 2.
- Trial name
- NCT00807261
- Testing
- Gemcitabine and Docetaxel
- Volunteers
- 30 people
- Sponsor
- Asan Medical Center
Solid Tumors
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced…
- Trial name
- NCT00500422
- Testing
- Doxil, Gemcitabine, Velcade
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
NeoSAMBA: Neoadjuvant: Does the Sequence of Anthracycline and Taxane Matters: Before or After?
The purpose of this study is to evaluate the usual and the reverse sequence of an anthracycline followed by a taxane in locally advanced breast cancer.
- Trial name
- NeoSAMBA (NCT01270373)
- Testing
- FAC x 3 followed by Docetaxel x 3, Docetaxel x 3 followed by FAC x 3
- Where
- Brazil
- Volunteers
- 112 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Solid Tumors, Ovarian Cancer
A Phase I Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
ALM201/0001 is a Phase I, open-label, dose-escalation study of the safety, tolerability and pharmacokinetics (PK) of ALM201. Part 1 will be a dose-escalation study.
- Trial name
- NCT03427073
- Testing
- ALM201
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Almac Discovery
Esophageal Cancer, Gastric Cancer
Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor.
- Trial name
- NCT00032123
- Testing
- erlotinib hydrochloride
- Where
- 107 sites in United States, Canada
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Methylated Genes in Blood as Biomarkers for Advanced Lung Cancer
The purpose of this study is to study whether the presence of lung cancer in your body can be detected by testing the blood, and if the results of these blood tests change as your tumor shrinks or grows.
- Trial name
- NCT00579462
- Testing
- Blood and Tissue studies
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and either kill them or deliver radioactive cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00003868
- Testing
- cyclophosphamide, methotrexate, allogeneic bone marrow transplantation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
This randomized phase III trial studies octreotide acetate and recombinant interferon alfa-2b to see how well it works compared to octreotide acetate and bevacizumab in treating patients with high-risk neuroendocrine tumors that…
- Conditions
- Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1, Neuroendocrine Neoplasm, Neuroendocrine Tumor
- Trial name
- NCT00569127
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate
- Where
- 493 sites in United States
- Volunteers
- 427 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.